Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists
暂无分享,去创建一个
[1] Issa J Dahabreh,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. , 2008, Clinical therapeutics.
[2] A. Taher,et al. Recurrent skin reaction secondary to darbepoetin alfa for two months in a patient with chronic lymphocytic leukemia , 2007, American journal of hematology.
[3] C. Fernandes,et al. Anaphylactoid reaction to recombinant tissue plasminogen activator. , 2007, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.
[4] E. Savilahti,et al. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease , 2007, Acta paediatrica.
[5] P. Peloso,et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.
[6] T. Jansen,et al. Anaphylactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor? , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[7] L. Kappos,et al. Infusion-related hypersensitivity reactions during natalizumab treatment , 2006, Neurology.
[8] L. Salvagno,et al. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] B. Wallaert,et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions , 2006, Alimentary pharmacology & therapeutics.
[10] B. Chipps. Systemic reaction to omalizumab. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[11] L. Truedsson,et al. - 1-Predictors of infusion reactions during infliximab treatment in patients with arthritis , 2006 .
[12] J. Ménard,et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. , 2006, The Journal of rheumatology.
[13] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[14] B. Dijkmans,et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[15] S. Hsu,et al. Adalimumab-induced urticaria. , 2006, Dermatology online journal.
[16] P. Kouides,et al. Rituximab-induced leukocytoclastic vasculitis: a case report. , 2006, Archives of dermatology.
[17] T. Horn,et al. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. , 2006, Archives of dermatology.
[18] B. Thiers. Adalimumab for the Treatment of Patients With Moderately to Severely Active Psoriatic Arthritis: Results of a Double-blind, Randomized, Placebo-controlled TrialMease PJ, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group (Seattle Rheumatology Associates; et al) Arthritis Rheum , 2006 .
[19] G. Wall,et al. Possible drug rash with eosinophilia and systemic symptoms syndrome after exposure to epoetin alfa. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[20] P. Milkiewicz,et al. Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[21] J. Sany,et al. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis , 2005, Annals of the rheumatic diseases.
[22] D. Gladman,et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.
[23] A. Bennett,et al. Adalimumab-induced asthma. , 2005, Rheumatology.
[24] M. Fernández-Figueras,et al. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients , 2005, The British journal of dermatology.
[25] C. Kittas,et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. , 2005, Arthritis and rheumatism.
[26] P. Sørensen,et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy , 2005, Neurology.
[27] L. Mayer,et al. Monoclonal antibodies, immunogenicity, and associated infusion reactions. , 2005, The Mount Sinai journal of medicine, New York.
[28] A. Sanyal,et al. Antibody-Mediated Pure Red Cell Aplasia Due to Epoetin Alfa During Antiviral Therapy of Chronic Hepatitis C , 2005, The American Journal of Gastroenterology.
[29] R. Baldassano,et al. Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium , 2005, Inflammatory bowel diseases.
[30] A. Tonnel,et al. Accoutumance médicamenteuse à l'infliximab dans la maladie de Crohn , 2005 .
[31] M. Scheinberg,et al. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. , 2005, Arthritis and rheumatism.
[32] R. Priori,et al. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. , 2005, Rheumatology.
[33] A. H. Diwan,et al. Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma , 2005, Leukemia & lymphoma.
[34] B. Wallaert,et al. [Desensitisation to infliximab in patients with Crohn's disease]. , 2005, Revue des maladies respiratoires.
[35] M. Chávez-López,et al. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. , 2005, Allergologia et immunopathologia.
[36] C. Rosé,et al. Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. , 2004, The Journal of rheumatology.
[37] S. Hanauer,et al. An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease , 2004, American Journal of Gastroenterology.
[38] J. Guilhou,et al. Psoriatic lesions induced by antitumour necrosis factor‐α treatment: two cases , 2004, The British journal of dermatology.
[39] S. Targan,et al. A Pilot Study of Adalimumab in Infliximab-Allergic Patients , 2004, Inflammatory bowel diseases.
[40] T. Giese,et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. , 2004, European journal of gastroenterology & hepatology.
[41] R. Aster,et al. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug , 2004, Journal of thrombosis and haemostasis : JTH.
[42] R. Baldassano,et al. Human Antichimeric Antibody in Children and Young Adults with Inflammatory Bowel Disease Receiving Infliximab , 2004, Journal of pediatric gastroenterology and nutrition.
[43] P. Lipsky,et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.
[44] P. Rutgeerts,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.
[45] J. Kremer,et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.
[46] J. Dutcher,et al. Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin Lymphoma , 2004, Leukemia & lymphoma.
[47] A. Zinsmeister,et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.
[48] B. Hellerstedt,et al. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] S. Helfgott,et al. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? , 2003, The Journal of rheumatology.
[50] P. Emery,et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. , 2003, The Journal of rheumatology.
[51] A. Erhardt,et al. Arzneimittelexanthem durch pegyliertes Interferon-α2b , 2003, Der Hautarzt.
[52] E. Haddad,et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab , 2003, Transplantation.
[53] W. Berger,et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[54] K. McGrath,et al. Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. , 2003, Allergy and asthma proceedings.
[55] D. McGill,et al. Severe hypotension complicating primary angioplasty: allergy to abciximab , 2003, Allergy.
[56] S. Plevy,et al. The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.
[57] W. Tyler,et al. Worsening injection site reactions with continued use of etanercept. , 2003, Journal of drugs in dermatology : JDD.
[58] M. Peppercorn,et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.
[59] K. Tada,et al. Severe infusion reaction induced by trastuzumab: A case report , 2003, Breast cancer.
[60] A. Domm. A patient's reaction to infliximab. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[61] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[62] C. Garcia,et al. Anaphylactic shock after retreatment with basiliximab. , 2003, Transplantation proceedings.
[63] R. Schneider,et al. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. , 2003, The Journal of rheumatology.
[64] B. Korelitz,et al. Red man syndrome and infliximab. , 2003, Journal of clinical gastroenterology.
[65] W. Crandall,et al. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model , 2003, Alimentary pharmacology & therapeutics.
[66] E. Jourdan,et al. Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative Disorder , 2003, Leukemia & lymphoma.
[67] A. Erhardt,et al. [Drug-induced exanthema caused by pegylated interferon-alpha 2b]. , 2003, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[68] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[69] K. Woodside,et al. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody , 2002, Transplantation.
[70] G. Mead,et al. Stevens-Johnson syndrome after treatment with rituximab. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[71] S. Hanauer,et al. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians , 2002, American Journal of Gastroenterology.
[72] Jon E. Stahlman,et al. Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin). , 2002, The Journal of allergy and clinical immunology.
[73] I. Betlloch,et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. , 2002, Archives of dermatology.
[74] K. Eckardt,et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. , 2002, Journal of the American Society of Nephrology : JASN.
[75] Y. Herishanu. Rituximab‐induced serum sickness , 2002, American journal of hematology.
[76] E. Matteson,et al. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. , 2002, Arthritis and rheumatism.
[77] S. Kugathasan,et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction , 2002, American Journal of Gastroenterology.
[78] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[79] M. Castro,et al. Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease. , 2002, The Journal of pediatrics.
[80] John A. Godfrey,et al. Delayed Hypersensitivity Reaction and Acute Respiratory Distress Syndrome Following Infliximab Infusion , 2002, Inflammatory bowel diseases.
[81] D. Palisaitis,et al. Potential Anaphylactic Shock with Abciximab Readministration , 2002, Pharmacotherapy.
[82] D. Moneret-vautrin,et al. T cell mediated allergy to abciximab , 2002, Allergy.
[83] M. O'connor,et al. Anaphylaxis-like reaction to infliximab in a patient with Crohn's disease. , 2002, Digestive diseases and sciences.
[84] R. Quinet,et al. Etanercept and infliximab associated with cutaneous vasculitis. , 2002, Rheumatology.
[85] J. Rossi,et al. Rituximab-Induced Vasculitis , 2001, Dermatology.
[86] C. Pechlaner,et al. Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase. , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[87] L. Grammer,et al. Hypersensitivity to IFN‐α , 2001 .
[88] A. Levinson,et al. Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. , 2001, Archives of dermatology.
[89] M. Mannik,et al. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). , 2001, Arthritis and rheumatism.
[90] C. Ritchlin,et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. , 2001, Archives of dermatology.
[91] D. L. Brown,et al. An urticarial IgE-mediated reaction to interferon β-1b , 2001, Neurology.
[92] L. Putte,et al. Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment. , 2001 .
[93] S. Kugathasan,et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. , 2001, Inflammatory bowel diseases.
[94] D. L. Brown,et al. An urticarial IgE-mediated reaction to interferon beta-1b. , 2001, Neurology.
[95] S. Hanauer,et al. Infliximab in Crohn's disease: first anniversary clinical experience , 2000, American Journal of Gastroenterology.
[96] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[97] T. Schaible. Long term safety of infliximab. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[98] A. Özden,et al. Severe anaphylactic reaction to infliximab: report of a case , 2000, American Journal of Gastroenterology.
[99] J. Hyams. Use of Infliximab in the Treatment of Crohn's Disease in Children and Adolescents , 2000, The Journal of pediatrics.
[100] C. Possidente,et al. Anaphylactoid Reaction to Muromonab‐CD3 in a Pediatric Renal Transplant Recipient , 2000, Pharmacotherapy.
[101] P. Lipsky,et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.
[102] T. Nichols,et al. Possible anaphylactic reaction to abciximab , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[103] W. Heiss,et al. Evidence of anaphylaxy after alteplase infusion. , 1999, Stroke.
[104] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[105] H. Kaminski. Achalasia and myasthenia gravis in a patient with thymoma , 1999, Neurology.
[106] L. Ostrosky-Zeichner,et al. Severe anaphylaxis with recombinant interferon beta , 1999, Neurology.
[107] D. Furst,et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.
[108] E. Tindall,et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.
[109] L. Moscinski,et al. Type III hypersensitivity reaction with the use of interferon‐α , 1997, American journal of hematology.
[110] J. C. Orta Cuevas,et al. Probable hypersensitivity reaction to filgrastim. , 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[111] R. Weiss,et al. Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[112] D. Abramowicz,et al. The IgE humoral response in OKT3-treated patients. Incidence and fine specificity. , 1996, Transplantation.
[113] B. Taillan,et al. [No cross hypersensitivity between molgramostim and filgrastime: apropos of a case]. , 1995, Therapie.
[114] W. Paul,et al. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3 , 1994, The Journal of experimental medicine.
[115] D. Mccluskey,et al. Anaphylactoid reaction after injection of alteplase , 1993, The Lancet.
[116] C. King,et al. Generalized eczematous reaction to erythropoietin , 1993, Contact dermatitis.
[117] M. Turner,et al. Late reactions during initial OKT-3 treatment , 1993 .
[118] D. Abramowicz,et al. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. , 1992, The New England journal of medicine.
[119] D. Massel,et al. Anaphylactoid reaction during an infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction. , 1991, The Canadian journal of cardiology.
[120] A. S. Cheung,et al. Anaphylactic hypersensitivity reaction after repeat OKT3 treatment , 1991, The Lancet.
[121] J. Georgitis,et al. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. , 1991, Annals of allergy.
[122] F. Finkelman,et al. Anti-CD3 antibody induces rapid expression of cytokine genes in vivo. , 1990, Journal of immunology.
[123] D. Abramowicz,et al. Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. , 1990, Journal of immunology.